ISSN 1662-4009 (online)

ey0019.2-9 | Neonatal diabetes mellitus | ESPEYB19

2.9. SGLT2 inhibitors therapy protects glucotoxicity-induced [beta]-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress

ZA Shyr , Z Yan , A Ustione , EM Egan , MS Remedi

PLoS One. 2022 Feb 18;17(2):e0258054. doi: 10.1371/journal.pone.0258054. PMID: 35180212.Brief Summary: This mouse model of diabetes describes how early administration of sodium glucose transporter 2 (SGLT2) inhibitors can protect pancreatic beta-cells from glucotoxicity damage. Early use of SGLT2 inhibitors can revert/prevent beta-cell failure in mice with diabetes due to KATP channel de...

ey0019.2-11 | Neonatal diabetes mellitus | ESPEYB19

2.11. Cognitive deficits and impaired hippocampal long-term potentiation in KATP-induced DEND syndrome

S Yahil , DF Wozniak , Z Yan , S Mennerick , MS Remedi

Proc Natl Acad Sci U S A. 2021 Nov 9;118(45):e2109721118. doi: 10.1073/pnas.2109721118. PMID: 34732576.Brief Summary: In a mouse model of KATP neonatal diabetes mellitus, this study examined the mechanisms of cognitive deficits and development delay observed in some patients with this form of diabetes. The cognitive deficits and development delay appeared to be independent of the diabetes per...

ey0019.2-10 | Neonatal diabetes mellitus | ESPEYB19

2.10. Genetic reduction of glucose metabolism preserves functional [beta]-cell mass in KATP-induced neonatal diabetes

Z Yan , M Fortunato , ZA Shyr , AL Clark , M Fuess , CG Nichols , MS Remedi

Diabetes. 2022 1;71(6):1233-1245. doi: 10.2337/db21-0992. PMID: 35294000.Brief Summary: This mouse model of diabetes tested the hypothesis that reducing the metabolic flux (rate of metabolism) in the beta cell can prevent beta-cell failure and preserve beta-cell mass. Reducing glucose metabolism may be a mechanism for preventing glucotoxicity-induced loss of functional beta-cell mass in diabetes. <...